Effects of celecoxib on major prostaglandins in asthma

Clinical and Experimental Allergy

Volumn 41, Issue 1, 2011, Pages 36-45

  Daham, K ^a,b   Song, W L ^c   Lawson, J A ^c   Kupczyk, M ^b   Gulich A ^a,b   Dahlen S E ^b   FitzGerald, G A ^c   Dahlen B ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Asthma; Celecoxib; NSAIDs; Salivary prostaglandin E2; Urinary prostaglandin metabolites

Indexed keywords

11,15 DIOXO 9 HYDROXY 2,3,4,5 TETRANORPROSTANE 1,20 DIOIC ACID; 11ALPHA HYDROXY 9,15 DIOXO 2,3,4,5 TETRANOR PROSTANE 1,20 DIOIC ACID; ARACHIDIC ACID; CELECOXIB; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; THROMBOXANE A2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; FRACTION OF EXHALED NITRIC OXIDE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG FUNCTION; MALE; METABOLITE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; SALIVA; SINGLE BLIND PROCEDURE; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; URINALYSIS; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; ASTHMA; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSTAGLANDINS; PYRAZOLES; RESPIRATORY FUNCTION TESTS; SULFONAMIDES; YOUNG ADULT;

EID: 78650006980     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2010.03617.x     Document Type: Article

References (44)

1. Vane JR. Inhibition of prostaglandin biosynthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232-5.
2. Kujubu DA, Fletcher BS, Vamum BC, Lim RW. Herschman HR, TIS 10, a phorbol ester tumor promoterinducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266:12866-72.
3. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992; 89:3917-21.
4. Rovati GE, Sala A, Capra V, Dahlén S-E, Folco GC. Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends Pharmacol Sci 2010; 31:102-7.
5. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96:272-7.
6. Grosser T, Yu Y, FitzGerald GA. Emotion recollected in tranquility; lessons from the COX-2 saga. Ann Rev Med 2010; 61:17-33.
7. 2. Lancet 1995; 345:436-8.
8. Curzen N, Rafferty P, Holgate ST. Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax 1987; 42:946-52.
9. 4 in humans. Effect of indomethacin. Am Rev Respir Dis 1990; 141:1441-5.
10. Sestini P, Refini RM, Pieroni MG, Vaghi A, Robuschi M, Bianco S. Different effects of inhaled aspirinlike drugs on allergen-induced early and late asthmatic responses. Am J Respir Crit Care Med 1999; 159:1228-33.
11. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62:1111-8.
12. Saroea HG, Inman MD, O'Byrne PM. U46619-induced bronchoconstriction in asthmatic subjects is mediated by acetylcholine release. Am J Respir Crit Care Med 1995; 151:321-4.
13. 2 in normal and asthmatic men. N Engl J Med 1984; 311:209-13.
14. 1 and CRTH2 in promoting allergic responses. Br J Pharmacol 2008; 153:S191-9.
15. Matsuoka T, Hirata M, Tanaka H et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000; 287:2013-7.
16. 2 generation via prostaglandin endoperoxide synthase-2. J Immunol 1995; 155:4445-53.
17. Shiraishi Y, Asano K, Niimi K et al. Cyclooxygenase-2/prostaglandin D2/CRTH2 pathway mediates double-stranded RNA-induced enhancement of allergic airway inflammation. J Immunol 2008; 180:541-9.
18. 2 in mice and humans. J Biol Chem 2008; 283:1179-88.
19. Fries S, Grosser T, Price TS et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006; 130:55-64.
20. Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Amayasu H. Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000; 106:1201-2.
21. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31:219-25.
22. Gyllfors P, Bochenek G, Overholt J et al. Biochemical and clinical evidence that aspirin-intolerant asthmatics tolerate the cyclooxygenase-2 (COX-2) selective analgetic drug celecoxib. J Allergy Clin Immunol 2003; 111:1116-21.
23. O'Sullivan S, Dahlén B, Dahlén S-E, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9α, 11β-prostaglandin F2 following aspirin challenge supports mastcell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996; 98:421-2.
24. Gaber F, Daham K, Higashi A et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008; 63:1076-82.
25. Bäck M, Hlawaty H, Labat C, Michel J-B, Brink C. The Oral Cavity and Age: a Site of Chronic Inflammation? PLoS One 2007; 2:e1351.
26. 2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004; 334:266-75.
27. 2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 2008; 63:27-34.
28. Yin H, Gao L, Tai HH, Murphey LJ, Porter NA, Morrow JD. Urinary prostaglandin F2alpha is generated from the isoprostane pathway and not the cyclooxygenase in humans. J Biol Chem 2007; 282:329-36.
29. 2 in vivo. Thorax 2004; 59:453-5.
30. 2 generation by inhibiting cyclo-oxygenase-2 in cultured human mast cells. Clin Exp Allergy 1999; 29:1129-35.
31. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77:590-4.
32. O'Sullivan S, Roquet A, Dahlén B, Dahlén S-E, Kumlin M. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. Clin Exp Allergy 1998; 28:1332-9.
33. O'Sullivan S, Roquet A, Dahlén B et al. Evidence for mast cell activation during exercise-induced bronchoconstriction. Eur Respir J 1998; 12:345-50.
34. 2 release protects against mannitol-induced airway narrowing. Eur Respir J 2006; 27:944-50.
35. 4 and histamine in asthmatics. Am Rev Respir Dis 1992; 146:96-103.
36. Kippelen P, Larsson J, Anderson SD, Brannan J, Dahlén B, Dahlén SE. Effect of sodium cromoglycate on mast cell mediators during hyperpnea in athletes. Med Sci Sports Exerc 2010, [Epub ahead of print].
37. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346:1699-705.
38. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-73.
39. Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy 2002; 32:1484-1490.
40. 2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003; 111:743-9.
41. Higashi N, Mita H, Ono E et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125:1084-91.
42. Sebaldt RJ, Sheller JR, Oates JA, Roberts LJ II, FitzGerald GA. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci USA 1990; 87:6974-8.
43. Hamberg M. Inhibition of prostaglandin synthesis in man. Biochem Biophys Res Commun 1972; 49:720-6.
44. Seyberth HW, Sweetman BJ, Frölich JC, Oates JA. Quantification of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976; 11:381-97.